- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05374967
The Effect of a Multimodal Lifestyle Intervention on Chronic Fatigue in Patients With Inflammatory Bowel Disease (Multi-IBD)
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: R. Loveikyte, MD
- Phone Number: 0031715297902
- Email: patientenibd@lumc.nl
Study Locations
-
-
-
Leiden, Netherlands, 2333ZA
- Leiden University Medical Center (LUMC)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adults (≥18 years old)
- Established IBD diagnosis (Crohn's disease, Ulcerative colitis, or IBD-unclassified)
- Biochemical remission (fecal calprotectin ≤150 mcg/g)
- Clinically significant fatigue (visual analog score 4-8 out of 10)
- Willing and able to attend digital group sessions as a part of the intervention
Exclusion Criteria:
- Documented comorbidities such as severe cardiac failure (classified as NYHA 3-4), chronic kidney disease, myelodysplastic syndrome, Chronic Obstructive Pulmonary Disease (COPD), inherited metabolic diseases (e.g., phenylketonuria, mitochondrial or uric acid cycle pathologies), diabetes type 1
- Documented history of malignancy within the last three years before inclusion except for dermatological cancers such as basal cell carcinoma or squamous cell carcinoma
- Documented history of psychiatric diseases, eating disorders, or addiction. Exception: patients with a history of depression and/or under treatment with antidepressants; however, at inclusion the patients must have a Hospital Anxiety Depression Scale (HADS) score <11 for the depression subscale
- Documented familial hypercholesterolemia
- Diabetes type 2 treated with insulin or other medications such as sulfonylureas, glinides, alpha-glucosidase inhibitors, etc. The only exception is biguanides-metformin
- BMI <18.5 or >35 kg/m2
- Clinically significant anemia (Hb <7.0 mmol/l in females, Hb <8.0 mmol/l in males) with the exception of marginal normocytic or macrocytic anemia (MCV >100 fL and Hb >7.0 mmol/L for females and Hb >8.0 mmol/L for males) as a result of IBD-therapy related myelosuppression
- Vitamin B12 or folic acid deficiency
- Iron deficiency (defined as ferritin <30 μg/l)
- Vitamin D deficiency (<30 nmol/l)
- History of prior bariatric surgery or upper gastrointestinal surgery such as Roux-Y reconstruction or (partial) gastrectomy due to benign or malignant pathologies
- Pregnancy or active breastfeeding
- Unwillingness to follow the lifestyle program, i.e. people that do not want to eat fish, vegans
- Any change in IBD-related systemic medication within the last three months of intervention. Changes in medication dose are allowed up to 1 month before the start of the intervention. Exception: changing the route of administration (e.g., switching from intravenous infliximab to subcutaneous infliximab) or change in therapy due to side effects such as an allergic reaction or cutaneous conditions.
- Recent major surgery, e.g. laparotomy in the last four weeks
- Extended hospitalization (a >2-week admission) within four weeks before inclusion
- Unable to speak and understand Dutch language
- Participation in another study with lifestyle intervention or active consultation with a lifestyle coach on patient's initiative
- Previous participation in the IBD-tailored program by Voeding Leeft
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Control group
The control group will receive the current standard of care: an informational brochure on how to cope with fatigue.
|
The standard of care for patients with IBD suffering from chronic fatigue.
|
Experimental: Lifestyle intervention
Participants will undergo a multimodal lifestyle intervention, which focuses on nutrition, sleep, stress, and exercise.
The lifestyle intervention includes digital lessons/webinars and online counseling by a nutritionist and a lifestyle coach.
|
A digital lifestyle intervention divided into two phases:
During the Intensive Phase, participants will receive regular counseling by a nutritionist and a lifestyle coach in groups of 25 people. Participants will also follow five online meetings focusing on either nutrition, exercise, sleep, and stress. In addition, participants will have 24/7 access to an online platform that contains additional information, challenges, recipes, and peer-support groups. Finally, during the facultative phase, participants can attend smaller group sessions for additional counseling by a nutritionist or a lifestyle coach; these sessions will be organized every six to 12 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Fatigue at six months
Time Frame: Six months after starting the intervention
|
Percentage of patients who experience a reduction in fatigue at six months compared between the intervention and the control group.
The reduction in fatigue is defined as any increase in The Functional Assessment of Chronic Illness Therapy - Fatigue ((FACIT-F) score (0-160 with lower scores indicating worse fatigue) at six months compared with the baseline.
|
Six months after starting the intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean change in fatigue (FACIT-F)
Time Frame: at three months, at 12 months after the start of the intervention.
|
Mean change in fatigue (measured by FACIT-F questionnaire 0-160 with lower scores indicating worse fatigue) compared between the intervention and the control; compared at different study time points.
|
at three months, at 12 months after the start of the intervention.
|
Mean change in fatigue (fatigue VAS)
Time Frame: at three months, at 12 months after the start of the intervention.
|
Mean change in fatigue (measured by a fatigue visual analog scale (VAS) 0-10 with higher scores indicating worse fatigue) compared between the intervention and the control; compared at different study time points.
|
at three months, at 12 months after the start of the intervention.
|
Mean change in quality of life (EQ-5D VAS)
Time Frame: at three months, at six months, and at 12 months after the start of the intervention.
|
Mean change in quality of life (measured by EuroQoL 5 Dimension Visual Analog Score (EQ-5D VAS) 0-100 with higher scores indicating better quality of life) compared between the intervention and the control group; compared at different study time points.
|
at three months, at six months, and at 12 months after the start of the intervention.
|
Mean change in activity impairment
Time Frame: at six months and at 12 months after the start of the intervention.
|
Mean change in activity impairment (measured by Work Activity and Productivity Impairment: Inflammatory Bowel Disease (WPAI:IBD) 0-100% with higher percentages indicating greater impairment) questionnaire) compared between the intervention and the control group; compared at different study time points.
|
at six months and at 12 months after the start of the intervention.
|
Mean Clinically Important Difference in fatigue (FACIT-F)
Time Frame: at three months, at six months, and at 12 months after the start of the intervention.
|
Percentage of participants who reached the Mean Clinically Important Difference (MCID) in the FACIT-F (MCID = 4) scores compared between the intervention and control group at different time points.
|
at three months, at six months, and at 12 months after the start of the intervention.
|
Mean Clinically Important Difference in quality of life (SIBDQ)
Time Frame: at three months, at six months, and at 12 months after the start of the intervention.
|
Percentage of participants who reached the Mean Clinically Important Difference (MCID) in the SIBDQ (MCID = 9) scores compared between the intervention and control group at different time points.
|
at three months, at six months, and at 12 months after the start of the intervention.
|
Mean Clinically Important Difference in quality of life (EQ-5D VAS).
Time Frame: at three months, at six months, and at 12 months after the start of the intervention.
|
Percentage of participants who reached the Mean Clinically Important Difference (MCID) in the EQ-5D VAS (MCID = 4.2) scores compared between the intervention and control group at different time points.
|
at three months, at six months, and at 12 months after the start of the intervention.
|
Mean Clinically Important Difference in activity impairment (WPAI:IBD)
Time Frame: at six months and at 12 months after the start of the intervention.
|
Percentage of participants who reached the Mean Clinically Important Difference (MCID) in the WPAI:IBD (MCID= 7) scores compared between the intervention and control group at different time points.
|
at six months and at 12 months after the start of the intervention.
|
Mean change in physical exercise
Time Frame: at three months, at six months, and at 12 months after the start of the intervention.
|
Mean change in physical exercise (Short QUestionnaire to ASsess Health-enhancing physical activity (SQUASH) expressed in minutes of light/moderate/intensive exercise per week) compared between the intervention and the control group; compared at different study time points.
|
at three months, at six months, and at 12 months after the start of the intervention.
|
Mean change in perceived stress
Time Frame: at three months, at six months, and at 12 months after the start of the intervention.
|
Mean change in perceived stress (measured by Perceived Stress Scale (PSS) 0-40 with higher scores indicating higher perceived stress) compared between the intervention and the control group; compared at different study time points.
|
at three months, at six months, and at 12 months after the start of the intervention.
|
Mean change in coping with the illness
Time Frame: at three months, at six months, and at 12 months after the start of the intervention.
|
Mean change in coping (measured by Brief Illness Perception Questionnaire (B-IPQR) 0-10 with higher scores indicating a more threatening view of the illness) compared between the intervention and the control group; compared at different study time points.
|
at three months, at six months, and at 12 months after the start of the intervention.
|
Mean change in medical consumption
Time Frame: at three months, at six months, and at 12 months after the start of the intervention.
|
Mean change in medical consumption (measured by iMTA Medical Consumption Questionnaire (iMCQ) expressed as incurred costs per timepoint with higher costs indicating higher medical consumption) compared between the intervention and the control group; compared at different study time points.
|
at three months, at six months, and at 12 months after the start of the intervention.
|
Mean change in sleep quality
Time Frame: at three months, at six months, and at 12 months after the start of the intervention.
|
Mean change in sleep quality (measured by Pittsburgh Sleep Quality Index (PSQI) 0-21 with higher scores indicating worse sleep quality) compared between the intervention and the control group; compared at different study time points.
|
at three months, at six months, and at 12 months after the start of the intervention.
|
Correlation between fatigue and lifestyle (i.e., nutrition, exercise, sleep, stress)
Time Frame: baseline, at six months and at 12 months after the start of the intervention.
|
Correlation between changes in lifestyle parameters and effect parameters (i.e., which part of the lifestyle intervention (e.g., physical activity or sleep quality) improved fatigue scores).
|
baseline, at six months and at 12 months after the start of the intervention.
|
Correlation between locus of control and lifestyle changes
Time Frame: baseline, at six months and at 12 months after the start of the intervention.
|
Correlation between locus of control (Health Monitor questionnaire) at baseline and changes in lifestyle parameters and effect parameters.
|
baseline, at six months and at 12 months after the start of the intervention.
|
Cost-effectiveness of the intervention
Time Frame: at six months and at 12 months after the start of the intervention.
|
Cost-effectiveness of the intervention based on Quality-Adjusted Life Years (QALY's) expressed as 1 (perfect health) to 0 (dead).
|
at six months and at 12 months after the start of the intervention.
|
Mean change in dietary quality measured by Adjusted Mediterranean Diet Serving Score
Time Frame: at three months, at six months, and at 12 months after the start of the intervention.
|
Mean change in dietary quality (measured by Adjusted Mediterranean Diet Serving Score (Adjusted-MDSS) 0-17 with higher scores indicating better diet quality and adherence to the diet) compared between the intervention and the control group; compared at different study time points.
|
at three months, at six months, and at 12 months after the start of the intervention.
|
Mean change in quality of life (SIBDQ)
Time Frame: at three months, at six months, and at 12 months after the start of the intervention.
|
Mean change in quality of life (measured by Short Inflammatory Bowel Disease Questionnaire (SIBDQ) 10-70 with higher scores indicating better quality of life) compared between the intervention and the control group; compared at different study time points.
|
at three months, at six months, and at 12 months after the start of the intervention.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: P.W.J. Maljaars, MD, PhD, LUMC
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NL77752.058.21
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fatigue
-
Bakulev Scientific Center of Cardiovascular SurgeryFoundation for the Support of Physical Culture and Sports BECOME A CHAMPION; Autonomous Non-Profit organization of additional education sports school BECOME A CHAMPIONNot yet recruitingEfficacy, Self | Fatigue, Mental | Fatigue; Muscle, Heart | Fatigue; CombatRussian Federation
-
Universita di VeronaUniversity of Southern CaliforniaCompletedDiet, Healthy | Fasting | Fatigue, Mental | Fatigue; Muscle, HeartItaly
-
Supplement Formulators, Inc.Completed
-
University of ZurichRecruitingVocal FatigueSwitzerland
-
KU LeuvenCompleted
-
Société des Produits Nestlé (SPN)Maastricht University Medical CenterCompleted
-
University of Applied Sciences for Health Professions...University of Wisconsin, MilwaukeeCompleted
-
Taoyuan General HospitalCompleted
-
Alaa Yousri Mahmoud AtiaUnknownMuscle FatigueEgypt
-
University Hospital, Clermont-FerrandLaboratoire des Adaptations Métaboliques à l'Exercice en conditions Physiologiques...CompletedNeuromuscular FatigueFrance
Clinical Trials on Control group
-
Tasly Pharmaceutical Group Co., LtdCompleted
-
Henan Cancer HospitalRecruitingChemotherapy | Immune Checkpoint Inhibitor | Locally Advanced Gastric CarcinomaChina
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)Completed
-
International University of La RiojaRecruiting
-
Romanian Society of Anesthesia and Intensive CareUniversity of Medicine and Pharmacy "Victor Babes" Timisoara; Timişoara County...Completed
-
The University of Hong Konghong Kong Cancer FundCompletedBreast Cancer | Yoga Therapy | Shoulder Joint Motion | Scar Contracture
-
University of PernambucoUnknown
-
Yonsei UniversityUnknownAdvanced Gastric Cancer | Neoadjuvant Chemotherapy | Palliative ChemotherapyKorea, Republic of
-
Physicians Committee for Responsible MedicineMetropolitan Police Department of Washington, D.C.SuspendedDiabetes Mellitus, Type 2 | Overweight | Blood PressureUnited States
-
Istanbul University - Cerrahpasa (IUC)Active, not recruiting